Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endoscopic Procedures Nose Up in ENT Market

This article was originally published in Start Up

Executive Summary

Ear, nose and throat surgery is the oldest surgical specialty in the US, and until recently, its age was all too apparent. Before the mid 1980s, surgeries for sinusitis were performed in much the same way they'd been done since the turn of the century-through incisions in the face. But in the last 20 years, functional endoscopic sinus surgery was introduced, coupled with CT scanning technologies that have improved the diagnosis of sinusitis. Today, according to US Surgical Procedure Volumes, a report recently published by the Medtech Insight division of FDC-Windhover, the majority of these procedures employ endoscopic techniques performed on an outpatient basis. Now, endoscopic access is the platform upon which start-ups are fixing particular problems in sinus surgeries.

You may also be interested in...



Ethicon Buys Acclarent: Can This Exit Open Up ENT?

Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?

Ethicon Buys Acclarent: Can This Exit Open Up ENT?

Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?

Acclarent: Can Balloons Open Sinuses and the ENT Device Market?

Acclarent is developing interventional technology for the sinuses, targeting a clinical specialty unfamiliar with these techniques, in the hope of expanding an under-served device area. But will ENT surgeons welcome the change?

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel